Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Giovanni Tafuri"'
Autor:
Federico Villa, Aurora Di Filippo, Andrea Pierantozzi, Armando Genazzani, Antonio Addis, Gianluca Trifirò, Agnese Cangini, Giovanni Tafuri, Daniela Settesoldi, Francesco Trotta
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionIt is well acknowledged that the price of orphan drugs is normally higher than that resulting from the value-based pricing. A correlation between the cost of therapy for orphan drugs and the epidemiology (prevalence and incidence) of the
Externí odkaz:
https://doaj.org/article/afb495ca257e4a7d93148e83fe67162f
Autor:
Denis Lacombe, Ad Schuurman, Jessica Imbert, Jordi Llinares Garcia, Valentina Strammiello, Ansgar Hebborn, Flora Giorgio, Edith Frénoy, Giovanni Tafuri, Niklas Hedberg, Ingvil von Mehren Sæterdal, Anne Willemsen, Chantal Belorgey, C. Favaretti, Zoe Garrett, Daniel Widmer, Anna Lefevre Skjöldebrand, Elena Petelos, François Houÿez, Marcus Guardian
Publikováno v:
International Journal of Technology Assessment in Health Care. 36:191-196
The European Network for Health Technology Assessment (EUnetHTA) organizes an annual Forum with stakeholders to receive feedback on its activities, processes, and outputs produced. The fourth edition of the EUnetHTA Forum brought together representat
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 22(3)
The EU Orphan Regulation has successfully stimulated RD of medicines for rare diseases, resulting in a substantial increase of orphan designations and authorized orphan medicinal products in the EU during last decade. Despite such advances, access to
Autor:
Federico, Villa, Claudio, Jommi, Gianluca, Altamura, Sara, Antignani, Agnese, Cangini, Ida, Fortino, Mario, Melazzini, Francesco, Trotta, Giovanni, Tafuri
Publikováno v:
Recenti progressi in medicina. 111(2)
Italy was used as a case study to investigate the determinants of the difference between the price proposal for medicines submitted by the industry and the final negotiated price (∆P). Data was gathered through the information system used by Italia
Autor:
Federico, Villa, Jommi, Claudio, Gianluca, Altamura, Sara, Antignani, Agnese, Cangini, Ida, Fortino, Mario, Melazzini, Francesco, Trotta, Giovanni, Tafuri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4050::3bc0b36db54acafc080e2cc63d5eef92
http://hdl.handle.net/11565/4027425
http://hdl.handle.net/11565/4027425
Autor:
Spiros Vamvakas, Caridad Pontes, Guido Rasi, Sonia Garcia, Giovanni Tafuri, Elangovan Gajraj, Frank Pétavy, Inês Lucas, Eva-Maria Zebedin-Brandl, Andrea Molina, Mercè Obach, Anne d'Andon, Niklas Hedberg, Pierluigi Russo, Marco Petschulies, Hannah Bruehl, Steve Estevão, Jane Moseley, Marco Massari, Anja Schiel, Leeza Osipenko, Marc Van de Casteele
Publikováno v:
British Journal of Clinical Pharmacology. 84:1013-1019
Aims The parallel regulatory–health technology assessment scientific advice (PSA) procedure allows manufacturers to receive simultaneous feedback from both EU regulators and health technology assessment (HTA) bodies on development plans for new med
Autor:
Giuseppe Pimpinella, Leroy R. A. Lepelaars, Luca Pani, Francesco Trotta, Aukje K. Mantel-Teeuwisse, Hubert G. M. Leufkens, Gianluca Trifirò, Giovanni Tafuri, Francesca Renda
Publikováno v:
British Journal of Clinical Pharmacology. 84:738-763
Background and aims Biosimilars have been available in the European Union (EU) since 2006. However, their uptake in routine care is heterogeneous across countries. The aim of the present study was to compare the safety information of biosimilars and
Publikováno v:
Global Policy. 8:84-92
Managed entry agreements (MEAs) comprise a variety of instruments to reduce uncertainty arising from incomplete information on budget impact, cost-effectiveness, use in real life, and access to new therapies. MEAs have a number of advantages and limi
Publikováno v:
Br J Clin Pharmacol
Aim In April 2017 the Italian Medicine Agency (AIFA) developed new criteria to grant any new medicinal product with an innovative designation. The aim of this study is to describe this new model and how it works. Methods A retrospective descriptive a
Autor:
Ida Fortino, Gianluca Altamura, Francesco Trotta, Agnese Cangini, Federico Villa, Giovanni Tafuri, Michaela Tutone, S. Antignani, Claudio Jommi, Mario Melazzini
Objectives The aim of this paper is to investigate the determinants of the difference between the price proposal submitted by the industry and the final negotiated price. We used Italy as a case-study. Methods Data were gathered through the informati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7968a9a03338cec600901f6da5c54438
http://hdl.handle.net/11565/4020720
http://hdl.handle.net/11565/4020720